A PCR-based assay for the wild-type dystrophin gene transferred into the mdx mouse.
Myoblast transfer has emerged as a promising treatment for inherited myopathies such as Duchenne muscular dystrophy (DMD). Further development of the technique's therapeutic potential requires an experimental system in which issues of graft rejection can be clearly discriminated from those related to myoblast biology. Here we report the development and initial application of a quantitative assay for myogenic cells bearing a wild-type dystrophin gene following transfer into the mdx mouse. The technique relies upon the ability of a mutagenizing polymerase chain reaction (PCR) primer to create a new restriction site in the amplification production of the wild-type, but not the mdx dystrophin gene. The ratio of host to donor cells can be determined from muscle biopsies as small as 1 mg, regardless of donor H-2 background. This simple technique should allow a number of basic questions related to myoblast and direct gene transfer to be addressed using the mdx mouse model.
Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia 19104.
J B
JB
Shrager
A
A
Naji
A M
AM
Kelly
H H
HH
Stedman
D000595:Amino Acid Sequence; D000818:Animals; D004247:DNA / Q000032:analysis; D016189:Dystrophin / Q000235:genetics*; D015316:Genetic Therapy; D006801:Humans; D051379:Mice; D008810:Mice, Inbred C57BL; D008817:Mice, Mutant Strains; D008969:Molecular Sequence Data; D009132:Muscles / Q000637:transplantation; D009137:Muscular Dystrophy, Animal / Q000235:genetics* / Q000628:therapy; D017354:Point Mutation; D016133:Polymerase Chain Reaction / Q000379:methods; D012150:Polymorphism, Restriction Fragment Length; D014162:Transfection
D016189:Dystrophin; D004247:DNA